Bavarian Nordic A/S
CSE:BAVA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
144.15
283.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bavarian Nordic A/S
Accounts Receivables
Bavarian Nordic A/S
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Accounts Receivables
kr1.1B
|
CAGR 3-Years
46%
|
CAGR 5-Years
65%
|
CAGR 10-Years
26%
|
|
|
Genmab A/S
CSE:GMAB
|
Accounts Receivables
kr6.2B
|
CAGR 3-Years
36%
|
CAGR 5-Years
48%
|
CAGR 10-Years
52%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Accounts Receivables
kr234.7m
|
CAGR 3-Years
43%
|
CAGR 5-Years
483%
|
CAGR 10-Years
31%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Accounts Receivables
€33.1m
|
CAGR 3-Years
305%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
39%
|
|
|
F
|
Fluoguide AS
STO:FLUO
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Accounts Receivables
kr4.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The firm is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
See Also
What is Bavarian Nordic A/S's Accounts Receivables?
Accounts Receivables
1.1B
DKK
Based on the financial report for Jun 30, 2024, Bavarian Nordic A/S's Accounts Receivables amounts to 1.1B DKK.
What is Bavarian Nordic A/S's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
26%
Over the last year, the Accounts Receivables growth was -18%. The average annual Accounts Receivables growth rates for Bavarian Nordic A/S have been 46% over the past three years , 65% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet
